Table 1 Baseline characteristics of the trial participants
Characteristics | ATS/waiting (n = 32) | Waiting/ATS (n = 24) | Total (n = 56) |
|---|---|---|---|
Age, years, median (IQR) | 50 (42–62) | 49 (40–60) | 49 (42–61) |
Female, no. (%) | 21 (66) | 17 (71) | 38 (68) |
Body mass index, kg/m2, median (IQR) | 24 (22–26) | 22 (20–25) | 23 (21–25) |
Asthma Control Test,* median (IQR) | 18 (14–22) | 18 (15–21) | 18 (15–22) |
Asthma Quality of Life Questionnaire,† median (IQR) | 4.5 (3.6–5.3) | 4.7 (3.8–5.2) | 4.6 (3.7–5.2) |
Lung function, median (IQR) | |||
FEV1, L | 2.72 (2.02–3.38) | 2.43 (2.02–3.05) | 2.68 (2.03–3.20) |
FEV1, % | 88 (72–105) | 85 (70–102) | 85 (71–103) |
FVC, L | 3.54 (3.15–4.84) | 3.43 (2.87–4.45) | 3.52 (3.10–4.78) |
FEV1/FVC, % | 69 (63–77) | 69 (62–75) | 69 (62–76) |